EXCLUSIVE LICENCE. 2.1 Subject to the Operator's rights under this Agreement, the Client has a non-transferable licence to:
(a) occupy each of the Designated Hardstand Area and the Berth (as applicable) during the relevant agreed periods on an exclusive basis solely in connection with the provision of the relevant Services and the performance of Contractor Works in respect of the Nominated Vessel; and
(b) access and use Marine Hub facilities as permitted by the Operator from time to time.
2.2 The Client acknowledges and agrees that it has no right of exclusive occupation or use of any other part of the Marine Hub at any time.
2.3 The Client and its Representatives must not, and the Client shall procure that any Contractor and its Representatives do not, enter or access any other parts of the Marine Hub that are designated to, or occupied by, another client of the Marine Hub or any other areas within the Marine Hub designated by the Operator as a restricted area.
2.4 The licence granted under this Agreement is subject always to the Operator's right to enter the Designated Hardstand Area or Berth (as applicable) at any time pursuant to clauses 5.1(f) and 15 of the General Terms and Conditions.
2.5 The Operator makes no representation or warranty regarding the availability, adequacy, safety or suitability of the Marine Hub, the Designated Hardstand Area, the Berth or the Structures (as applicable) for any use or intended use. If the Operator or its Representatives provide any additional information to the Client or its Representatives during the Term, the Operator makes no representation or warranty regarding any such additional information.
EXCLUSIVE LICENCE. 2.1 The Licensor hereby grants to the Licensee a world-wide, exclusive and perpetual right to use the Licensed Trademarks and the Licensed Domain Names in connection with the following:
(a) all television and other visual and audio-visual services and products which are perceivable by individuals via screens of any nature whatsoever, whether the relevant technology exists at the date of this Licence Agreement or is developed in the future, and howsoever distributed;
(b) printed media, including but not limited to products and services consisting of printed copy devices, including but not limited to magazines and papers, meant for distribution to the public;
(c) any and all events (excluding musical events) relating or in connection with the services and products mentioned under (a) and (b);
(d) all services and products related to or in connection with any of the activities under (a) and (b), within and outside the company of the Licensee and its Affiliates such as, but without limitation e.g. on letterheads, personnel clothing, company cars, on web sites;
(e) merchandising the Licensed Trademarks and Licensed Domain Names to the extent related to the activities mentioned under (a) and (b);
(f) any and all services and products relating to or in connection with the rights granted under (a) and (b), including without limitation
(i) the marketing, promotion and advertising of these services and products, via any present or future means, including but not limited to radio, television, Internet, telephone (e.g. WAP), direct mail, newspaper and magazine advertising, billboards, and posters and any other present or future means of advertising; and
(ii) any spin-off activities and products relating to or in connection with the rights granted under (a) and (b), such as EPG services, web-site and mobile telecommunications services, ringtones and activities including without limitation SMS services and gaming, via any and all media and by all other methods now known or hereafter devised or developed, including but not limited to satellite, cable, wire, fibre, terrestrial over the air, home entertainment, software, hardware, internet, telephone (e.g. SMS, I-mode and WAP), all other forms of on-line and interactive and enhanced rights or media or similar applications or devices and, as far as screen originated: tape, disc, CD and/or DVD.
2.2 (a) Only the Licensee may use the Xxxxxxxx Trademarks and the Xxxxxxxx Domain Names in conjunction with or containing the words ...
EXCLUSIVE LICENCE. 3.1.1 On submission of a Work under clause 2.3, the Contributor grants to the Publisher an exclusive option to publish the Work for the period from the date of submission to the date of acceptance as set out in the Work Description.
3.1.2 If the Work has not been accepted for publication by the acceptance date, and the Publisher and the Contributor have not agreed otherwise, the exclusive option granted in clause 3.1.1 will lapse and the Contributor may deal with the Work as he or she sees fit.
EXCLUSIVE LICENCE. In consideration for publication in the above Journal, you hereby grant to the owner(s) SAGE Publications Ltd (the 'Proprietor') of the Journal identified above (the Journal title subject to verification by SAGE Publications Ltd ('SAGE')) the exclusive right and licence to produce, publish and make available and to further sub-license your article ('Article') and the accompanying abstract (all materials collectively referenced as the 'Contribution') prepared by you for the full legal term of copyright and any renewals thereof throughout the world in all languages and in all formats, and through any medium of communication now known or later conceived or developed. In the event you provide Supplemental Material to the Proprietor, you hereby grant to the Proprietor the non-exclusive right and licence to produce, publish and make available and to further sub-license the material, in whole or in part, for the full legal term of copyright and any renewals thereof throughout the world in all languages and in all formats, and through any medium of communication now known or later conceived or developed. By signing this Contributor Agreement I agree both to the above provisions and to the Terms of the Agreement outlined below. While copyright remains yours as the author, you hereby authorise the Proprietor to act on your behalf to defend your copyright should it be infringed and to retain half of any damages awarded, after deducting costs.
EXCLUSIVE LICENCE. 3.1 FBFC hereby grants ORTHOVITA and ORTHOVITA accepts a world-wide EXCLUSIVE LICENCE to use the KNOW-HOW, implement the PROCESS in ORTHOVITA's FACILITY and manufacture and sell, either directly or indirectly, the PRODUCTS.
3.2 ORTHOVITA, subject only to the payment obligations provided in Article 4, shall be freely entitled to grant sublicences or to assign the above licence to any third parties provided that ORTHOVITA secures that the third party concerned shall be bound by the confidentiality obligations set out in Article 8 to the same extent as ORTHOVITA. However, in case of assignment of the licence and unless FBFC has expressly agreed otherwise in writing, ORTHOVITA shall remain jointly and severally liable with the assignee for the full performance of the AGREEMENT.
EXCLUSIVE LICENCE. IJI hereby grants an exclusive licence to Viropro to market and produce the Products described herein in the Territories. The Territories shall include: Latin America, Thailand, China, Taiwan, Singapore and South Africa.
EXCLUSIVE LICENCE. 2.1 The Licensor hereby grants to SureNano Science the following exclusive licenses and rights and within the Territory, with no reservation of the continued right to use by the Licensor:
(a) to make, have made, use, offer to sell, sell, and import products containing or utilizing the LP Products and their underlying technology and intellectual property; and,
(b) to grant or enter into licenses, sub-licenses or agreements with third parties with respect to the exploitation of the LP Products. (the “Licence”)
EXCLUSIVE LICENCE. (a) Subject to the terms of this agreement, PGL hereby grants and MBC accepts, an exclusive licence, including the right to sublicense, to Exploit the PGL IP in the Territory during the Term.
(b) To the extent that the PGL IP includes a patent, the licence granted under clause 3.1
(a) ceases in respect of that patent on the expiry of that patent and the expiry of any patent extensions.
(c) After the Commencement Date, PGL will, at the request of MBC, provide samples of any Products it has which are relevant to the Field, including any intermediate forms and copies of the Products and any related Confidential Information.
(d) PGL will not sell Products relevant to the Field to End Users in the Territory nor supply Products relevant to the Field to any person who PGL has reasonable grounds to believe is likely to export the Products into the Territory.
(e) All enquiries PGL receives in respect of Products relevant to the Field to be delivered to End Users in the Territory will be referred to MBC.
EXCLUSIVE LICENCE. Subject to the terms and conditions of this Agreement, IPC hereby grants Taro and its Affiliates an exclusive and sub-licensable licence (i) to promote, market, distribute, offer for sale and sell the Product in the Territory; (ii) to use the IPC IP in connection with the activities authorized in this Section 2.1, and (iii) to reference IPC Dossier filed with Health Canada for the purpose of supporting its activities authorized in this Section 2.1 (collectively, the “License”). For greater certainty, it is confirmed that the License herein granted is an exclusive license which gives Taro the right to exercise the License to the exclusion of all Persons including IPC and Affiliates during the Term of this Agreement.
EXCLUSIVE LICENCE. (a) Subject to the terms of this agreement, PharmaSynth hereby grants and GTB accepts, an exclusive licence, including the right to grant sublicences, to Exploit the PharmaSynth IP in the Territory during the Term.
(b) To the extent that the PharmaSynth IP includes a patent, the licence granted under clause 3.1
(a) ceases in respect of that patent on the expiry of that patent and the expiry of any patent extensions.
(c) After the Commencement Date, PharmaSynth will, at the request of GTB, provide samples of any Products it has which are relevant to the Field, including any intermediate forms and copies of the Products and any related Confidential Information.
(d) For the purpose of assisting GTB to carry out its clinical trial PharmaSynth will if requested by GTB:
(i) Supply two (2) kg of the PI-88 bulk Active Pharmaceutical Ingredient (API) at no cost to GTB;
(ii) At the request of GTB, transfer ownership to GTB of a minimum of 20,000 vials of pre-filled lyophilised PI-88 (the equivalent of approximately 5 kg bulk API of PI-88), each containing 210 mg of PI-88 and a minimum of 20,000 vials of the lyophilised placebo, each containing 210 mg of the placebo, a minimum of 40,000 syringes prefilled with 1 ml of saline, associated needles and product packaging. Such GTB request of PharmaSynth to occur within 60 (sixty) days of the Execution of this Agreement. If GTB requests this transfer, the costs associated with the storage and further handling, including possible shipment of the material, upon the issue of this GTB request is assumed by GTB. The material is stored at Xxxxxxx Clinical in Allentown, Pennsylvania, USA.
(iii) supply up to a further 30 kg of API at $17,500 per kg; and
(iv) supply any further API at $25,000 per kg. GTB to pay for the API within 30 days of the request by GTB.
(e) PharmaSynth will not sell Products relevant to the Field to End Users in the Territory nor supply Products relevant to the Field to any person who PharmaSynth has reasonable grounds to believe is likely to export the Products into the Territory.
(f) All enquiries PharmaSynth receives in respect of Products relevant to the Field to be delivered to End Users in the Territory will be referred to GTB.
